Hengxinyuan Pharmaceutical

Wuhan Hengxinyuan Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise introduced through investment promotion by the Hubei Provincial People's Government. It is located in the Biomedicine Park of Wuhan Optics Valley Biopolis, covering an area of approximately 138 mu, with a total investment of 500 million yuan. It is a backbone enterprise of Optics Valley Biopolis integrating pharmaceutical R&D, production, and sales, and is also an enterprise invested in and constructed by the Biomedicine Park. For future export to international markets, the production base and equipment are built in accordance with EU GMP standards.
The company has built injection workshops, new plastic bottle workshop production lines, oral solid preparation workshops (including capsules, tablets, and granules), and production lines for refined bulk drug substances, and has achieved production capacity of considerable scale.
Currently, we have developed a series of Class 1 new drugs and improved new drugs with domestic PCT patents in the fields of anti-tumor, digestive, gynecological, and cardiovascular and cerebrovascular diseases.
In December 2012, the company's injection workshop passed the GMP certification of the National Medical Products Administration, and in March of the same year was issued the Drug GMP Certificate.
In June 2018, it passed GMP certification for dantrolene sodium bulk drug substance.
In June 2019, it passed GMP certification for dantrolene sodium oral solid preparations.
The company sincerely invites passionate, brave, confident, and diligent young people with lofty aspirations to join us in creating a brilliant tomorrow for Hengxinyuan.